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The growth of prostate cancer is regulated by the androgen receptor
(AR), which is a transcription factor that binds with steroid
hormones, co-activators and co-receptors of AR, and translocates
to the cell nucleus where the AR-complex initiates a number of
androgen-related gene transcription events. In patients with prostate
cancer treated with hormonal therapy, it is thought that with time
and exposure to anti-androgens, AR mutates. This mutation causes a
change in the regulation of prostate cancer cell growth, which may
become independent of treatments aimed to decrease the availability
of testosterone and dehydrotestosterone to the receptor.
There have been hundreds of AR mutations described, but one
of the most commonly observed is at codon 877 (Sack et al, 2001).
Mutation at codon 877 allows the tumour to become dependent for
its growth upon the drugs used to treat it (Monge et al, 2006). In
this situation, withdrawal of anti-androgens leads to a transient
response in 20–40% of patients (Kelly and Scher, 1993).
As prostate cancer progresses, it is thought that there is further
clonal evolution so that selection processes occur, leading to new
‘resistance’ to hormonal therapy, but this may not be an absolute
resistance. It is likely that this selection process causes changes
such that an individual’s tumour may respond to further hormonal
treatment; should that hormonal treatment be selective for the
mutation that has developed. Thus it is likely that patients will
respond to third- and fourth-line therapy with prednisone or
oestrogens or dexamethasone or hydrocortisone or other steroidal
agents. It is superficially and relatively straightforward to under-
stand why these responses should occur. This is because the
cellular receptors for these steroids are members of a supergene
family sharing considerable structural homology (Boonyaratanakornkit
and Edwards, 2007).
In this context, it is of interest to review the publication by
Shamash et al reported in this current edition of the British Journal
of Cancer. In their report, Shamash et al describe 56 patients with
prostate cancer who were treated with sequential hormonal
therapy and then, on progression, with a novel chemotherapy
regimen. During the period of treatment with chemotherapy,
hormonal therapy was discontinued. At the end of the treatment,
43 patients were re-challenged with hormonal therapy. Twenty-two
of these patients were non-castrate at the end of treatment and 21
castrate. Sixteen of this group of 43 patients (37%) then went on to
have a further PSA in response to either an LHRH agonist given
with an anti-androgen or to a combination of diethylstilboestrol
and dexamethasone. The responses were transient, but what is
remarkable is that 12 out of 28 patients, who were treated with
hormonal therapy following chemotherapy, went on to have
another transient PSA response after progression on maximal
androgen blockade (Shamash et al, 2007).
It is not clear whether these responses seen were due to induction
of hormonal sensitivity through an unknown mechanism or due to
regrowth of hormone-sensitive clones of cells which were previously
suppressed by the original anti-androgen therapies. Regardless of
mechanism, this paper has given oncologists and their patients
reasons to be grateful for a further option in the treatment
armamentarium, and this has been confirmed by Cox and Sundar in
two patients in correspondence published in this current edition of
the British Journal of Cancer (Cox and Sundar, 2007).
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